Artis BioSolutions, backed by venture club Oak HC/FT, has acquired Spain’s Syngoi Technologies. The deal consolidates the synthetic DNA supply chain.
Full Story:
Cross-border biotech M&A is heating up. Artis BioSolutions, a US platform backed by the powerful healthcare VC Oak HC/FT, has agreed to acquire Syngoi Technologies, a Spanish leader in synthetic DNA manufacturing. While a trade sale, the deal relies on the “Buy-and-Build” capital provided by Oak HC/FT’s syndicate of LPs.
Syngoi provides critical raw materials for gene therapies. By folding it into Artis, the club creates a transatlantic leader capable of serving Big Pharma globally.
Why It Matters:
“Life Science Sovereignty.” US funds are actively buying unique European biotech capabilities. This deal highlights the transatlantic corridor for life sciences private equity.
Source(s):
Fortune Term Sheet
